Abstract
A combination of pharmacological and genetic studies in mice confirmed that the Y1 and Y5 receptors mediate the potent orexigenic actions of exogenous NPY. Although the physiological role of NPY in causing obesity is less clear, potent and selective antagonists of both Y1 and Y5 have been developed. Some of the NPY antagonists have suitable pharmokinetic (PK) properties that allowed them to be evaluated in various rodent models of obesity. Several different Y1 and Y5 antagonists cause weight loss in rodent models, though confirmation that these effects are mechanism based has been limited. One Y5 antagonist, MK-0557 was evaluated in a 1-yr clinical trial and found to cause modest weight loss. Optimal NPY antagonist therapeutics for obesity may require blockade of both the Y1 and Y5 receptors.
Keywords: Neuropeptide Y, Y1, Y5, receptor, antagonist, obesity
Current Topics in Medicinal Chemistry
Title: NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs
Volume: 7 Issue: 17
Author(s): Douglas J. MacNeil
Affiliation:
Keywords: Neuropeptide Y, Y1, Y5, receptor, antagonist, obesity
Abstract: A combination of pharmacological and genetic studies in mice confirmed that the Y1 and Y5 receptors mediate the potent orexigenic actions of exogenous NPY. Although the physiological role of NPY in causing obesity is less clear, potent and selective antagonists of both Y1 and Y5 have been developed. Some of the NPY antagonists have suitable pharmokinetic (PK) properties that allowed them to be evaluated in various rodent models of obesity. Several different Y1 and Y5 antagonists cause weight loss in rodent models, though confirmation that these effects are mechanism based has been limited. One Y5 antagonist, MK-0557 was evaluated in a 1-yr clinical trial and found to cause modest weight loss. Optimal NPY antagonist therapeutics for obesity may require blockade of both the Y1 and Y5 receptors.
Export Options
About this article
Cite this article as:
MacNeil J. Douglas, NPY Y1 and Y5 Receptor Selective Antagonists as Anti-Obesity Drugs, Current Topics in Medicinal Chemistry 2007; 7 (17) . https://dx.doi.org/10.2174/156802607782341028
DOI https://dx.doi.org/10.2174/156802607782341028 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Management of Thymoma - A Review of the Status Quo with Practical Treatment Recommendations
Current Respiratory Medicine Reviews Genetic Dissection of Complex Traits In Silico: Approaches, Problems and Solutions
Current Bioinformatics Pediatric Heart Failure in the Developing World
Reviews on Recent Clinical Trials Insight View on Possible Role of Fluoroquinolones in Cancer Therapy
Current Topics in Medicinal Chemistry Cardioprotection Acquired Through Exercise: The Role of Ischemic Preconditioning
Current Cardiology Reviews Effects of Acarbose on Proinsulin and Insulin Secretion and their Potential Significance for the Intermediary Metabolism and Cardiovascular System
Current Diabetes Reviews GH Supplementation Effects on Cardiovascular Risk in GH Deficient Adult Patients: A Systematic Review and Meta-analysis
Endocrine, Metabolic & Immune Disorders - Drug Targets Potential Benefits and Limits of Psychopharmacological Therapies in Pervasive Developmental Disorders
Current Clinical Pharmacology Predictors of Left Ventricular Ejection Fraction Improvement after Radiofrequency Catheter Ablation in Patients with PVC-Induced Cardiomyopathy: A Systematic Review
Current Cardiology Reviews Association and Causal Relationship of Midlife Obesity and Related Metabolic Disorders with Old Age Cognition
Current Alzheimer Research Disparities in Cardiovascular Disease Risk in the United States
Current Cardiology Reviews The Biology and Therapeutic Potential of the DDAH/ADMA Pathway
Current Pharmaceutical Design Comprehensive Review of Cancer Chemopreventive Agents Evaluated in Experimental Carcinogenesis Models and Clinical Trials
Current Medicinal Chemistry Cardiovascular disease management through restrained inflammatory responses
Current Pharmaceutical Design Incretin-Based Therapy of Type 2 Diabetes Mellitus
Current Protein & Peptide Science Oxidative-Nitrosative Stress as a Contributing Factor to Cardiovascular Disease in Subjects with Diabetes
Current Vascular Pharmacology MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Memory Impairment is Associated with Serum Methylarginines in Older Adults
Current Alzheimer Research Risk Factors for Ischemic Heart Disease
Reviews on Recent Clinical Trials TNF-α and Ghrelin: Opposite Effects on Immune System, Metabolism and Mental Health
Protein & Peptide Letters